urogen.com - יחס שווי פעילות למכירות URGN

The EV/Revenue multiple for UroGen Pharma Ltd. (URGN) reflects a trend where the current level sits around 6636.08. The company is shielded from trade wars due to the humanitarian status of its developments. Its operating model relies on fully outsourcing drug production to third-party contractors under strict standards, while UroGen Pharma Ltd. (URGN) is implementing a breakthrough thermosensitive gel for targeted chemotherapy delivery without surgery.
URGN (UroGen Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For UroGen Pharma Ltd. (URGN), Jelmyto sales volume and pipeline development drive market valuation amid high operating expenses. The EV/Sales history reflects the ratio of the total enterprise value, net of debt, to daily revenue. This metric allows for an assessment of asset monetization efficiency without distortions from leverage. The stability of the trend confirms the model's resilience, yet it masks the risks of a sharp correction. It is critical for investors to correlate this indicator with the expected FDA decision.